Levi & Korsinsky, LLP announces that a GERN class action lawsuit has been commenced on behalf of investors who purchased Geron Corporation (GERN) securities between March 19, 2018 and September 26, 2018. For more on the Geron Corporation Class Action please contact us today.

According to the Geron Corporation lawsuit, the filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

TO LEARN MORE ABOUT THE GERN CLASS ACTION, VISIT: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?wire=9&prid=5348

If you suffered a loss in Geron Corporation you have until March 23, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com